Last reviewed · How we verify
NCT05950724
RENAL: Randomized Clinical Trial of TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant
EARLY_PHASE1 trial testing Etanercept Injection [Enbrel] in Lung Transplant; Complications in 20 participants. Enrolling by invitation.
1 December 2026
Quick facts
| Lead sponsor | Northwestern University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 17 September 2023 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Etanercept Injection [Enbrel] — full drug profile →
Conditions studied
- Lung Transplant; Complications — all drugs for Lung Transplant; Complications →
Sponsor
Northwestern University
Who can join
18 and older, any sex, with Lung Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Occurrence of kidney dysfunction immediately after lung transplant
Time frame: Immediately after lung transplant
Measured by serum creatinine blood tests -
Occurrence of kidney dysfunction post-operatively within 1 week after lung transplant
Time frame: Within 1-7 days after lung transplant
Measured by serum creatinine blood tests -
Occurrence of kidney dysfunction post-operatively within 1 month after lung transplant
Time frame: Up to 30 days after lung transplant
Measured by serum creatinine blood tests
Sponsor's own description
The purpose of this study is to assess whether TNFa antibody use before lung transplant can prevent kidney injury after lung transplant.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05950724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Transplant; Complications
Currently open trials in the same condition.
- NCT06399302 — Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes · recruiting
- NCT05836922 — Association Between Renal Regional Oxygen Saturation Measured by Near-InfraRed Spectroscopy and Postoperative Renal Fail · recruiting
- NCT04469842 — Early Use of Long-acting Tacrolimus in Lung Transplant Recipients · EARLY_PHASE1 · recruiting
- NCT05526950 — Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb) · NA · recruiting
- NCT05050955 — AlloSure Lung Assessment and Metagenomics Outcomes Study · active not recruiting
Other Northwestern University trials
Trials by the same sponsor.
- NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
- NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
- NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
- NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
- NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05950724 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwestern University
- Last refreshed: 7 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05950724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing